Scopus BioPharma Inc. (SCPS)
| Market Cap | 25.25K +100.0% |
| Revenue (ttm) | n/a |
| Net Income | -8.70M |
| EPS | -0.31 |
| Shares Out | 42.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,076 |
| Open | 0.0006 |
| Previous Close | 0.0006 |
| Day's Range | 0.0004 - 0.0006 |
| 52-Week Range | 0.000001 - 0.0100 |
| Beta | 31.10 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About Scopus BioPharma
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) ... [Read more]
News
Scopus BioPharma’s Duet presents data on DUET-102 with PD-1 blockade
Scopus BioPharma and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activit...
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”), a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical...
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — Announces Key Scientific Data to be Presented at the 37th Annual Meeting and Exposition of the Society for Immunotherapy of Cancer
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet med...
Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value
Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated
Scopus BioPharma Announces Biotechnology Industry Leader Rejoins Board of Directors
Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma Raphael (“Rafi”) Hofstein, Ph.D. Brings Invaluable Experience to Scopus BioPharma
Scopus BioPharma's Subsidiary — Duet BioTherapeutics — to Present at the 3rd Annual STING & TLR-Targeting Therapies Summit
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on TLR9 Activation and STAT3 Inhibition: A Bifunctional Approach to Immuno-Oncology
Scopus BioPharma Provides Update Following Annual Meeting of Stockholders
Overwhelming Majority of Shares Voted by Unaffiliated Stockholders were in Favor of Scopus' Director Nominees
DR. MORRIS C. LASTER WINS PROXY CONTEST AS STOCKHOLDERS ELECT HIS NOMINEES TO SCOPUS BIOPHARMA INC.
NEW YORK and JERUSALEM, Jan. 6, 2022 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with other proxy participants, beneficially owns 6,006,000 shares of common stock, par value $0....
Scopus BioPharma Issues Open Letter to Stockholders Detailing Morris Laster's Campaign Against the Company
Latest Legal Claims by Laster Actually Call into Question his Stock Ownership
Scopus BioPharma Sends Letter Urging Stockholders to Vote “FOR ALL” of the Company's Director Nominees on the WHITE Proxy Card
Company's Director Nominees are Highly Qualified and Experienced with Track Records of Guiding Early-Stage Life Science Companies
Dr. Morris C. Laster Issues An Open Letter To Scopus BioPharma Inc. Stockholders In Connection With Upcoming Annual Meeting
NEW YORK and JERUSALEM, Dec. 6, 2021 /PRNewswire/ -- Dr. Morris C. Laster ("Dr. Laster"), who, together with the other proxy participants, beneficially owns 6,006,000 shares of common stock, par value...
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signif...
Scopus BioPharma to Present at the LD Micro Main Event
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to condu...
Scopus BioPharma to Present at MicroCap Rodeo's Fall Harvest Best Ideas Conference
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Data from two different studies benchmark Duet's proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice
Scopus BioPharma's Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its ...
Scopus BioPharma's Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Duet releases video depicting mechanism of action for its proprietary CpG-STAT3 inhibitors to coincide with Duet presentations at OTS Meeting Duet releases video depicting mechanism of action for its ...
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with signi...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet Therapeutics, will present on CpG-STAT3 RNA Silencing and Antisense inhibitors
China National Intellectual Property Administration Grants New Patent Covering DUET-02, One of Three Key CpG-STAT3 Inhibitors Comprising the Duet Platform
New patent covers compound and composition and methods of use for CpG-STAT3 Antisense inhibitor (CpG-STAT3ASO)
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Appointment of Marcin Kortylewski, Ph.D. as Senior Scientific Advisor
Dr. Kortylewski is the Leading Authority on Bi-Functional Oligonucleotide Cancer Therapeutics and a Professor in the Department of Immuno-Oncology at the Beckman Research Institute at City of Hope Nat...
Scopus BioPharma's Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to Present on Clinical Development of CpG-STAT3 Inhibitors Alan Horsager, Ph.D., President and Chief Executive Officer of Duet, to ...